Merger Possibility?
HINTS! We are all aware of Dr. Missling's series of 1000 share buys prior to 2015 CTAD. Here is a listing of Anavex's SEC 8K filings that has served as more than just hints to me.
7/5/2013 - Dr. Missling's first contract for three years through
July 5,2016
7/5/16 - First amendment to his contract to extend employment for three years and also provided a large salary raise and many options to be vested over the three year period.
7/7/16 - Clarification of options plus an addition of the following
"UPON A CHANGE OF CONTROL ALL PREVIOUSLY GRANTED BUT UNVESTED OPTIONS SHALL VEST"
7/22/16 - Further clarifications of Missling's options.
Here is the listing of the quantity and dates of options granted to the granted to the BOD on FORM 4s filed with the SEC.
...............7/16/16..........9/22/16
Bernd.........50,000.........100,000
Favus..........1,500.........100,000
Skarpelos.... 50,000......100,000
Missling........................500,000 (In addition to contract options)
Boenisch......................106,696
Steffen.........................100,000
9/28/16 MTA to Biogen filed with the SEC.
????? QUIET PERIOD ?????
Also, Dr. Missling has stated many times that there is no need for funds.
I have a feeling that the BOD has all of the information they need and I'll rely on that.
Here is an Bloomberg article about Biogen.
Biogen’s CEO Is Out After Management Changes, Stalled Sales
by Doni Bloomfield
July 21, 2016 — 7:07 AM EDT July 21, 2016 — 11:48 AM EDT
George Scangos to leave in ‘coming months’; search beginning
Adjusted earnings beat estimates; share buyback announced
George Scangos. Photographer: David Paul Morris/Bloomberg
Biogen Inc. Chief Executive Officer George Scangos, who helped build the U.S. drugmaker into a powerful player in multiple sclerosis treatments, will leave the company after a series of top managers were replaced and sales of its biggest product stalled.
Scangos, 68, will stay on until a replacement is found, Biogen said in a statement Thursday in which it also reported second-quarter earnings. In the last year, the Cambridge, Massachusetts-based company announced new heads of sales and research, and its biggest product, the multiple sclerosis pill Tecfidera, disappointed investors.
His departure wasn’t a shock, given the company’s recent performance, Michael Yee, an analyst with RBC Capital Markets Corp., said by e-mail. “This is one where people thought there could be change given all that has gone on in the past year or so. The company’s next leader will face many of the same challenges that Scangos did in recent years -- how to advance the research and development pipeline of a storied biotechnology company that has made big, risky bets in diseases like Alzheimer’s, with mixed results. They’ll also need to boost sales of current products, which have surprised investors -- for good and bad -- in the competitive multiple sclerosis market.
Biogen will likely look outside the company for a new chief, according to Geoffrey Porges, an analyst at Leerink Partners.
Swooping In
“I imagine what they’re looking for is someone who’s already running a smaller company or has a track record of leading an integrated business unit focused on the neurosciences,” he said. Biogen has said it plans to concentrate on neurological drugs, and is working to spin off its treatments for the blood-clotting disorder hemophilia as a separate public company.
(My emphasis here.)
